Ruxolitinib for tocilizumab-refractory severe COVID-19 infection

被引：32
作者：
Innes, Andrew J. [1 ,2 ]
Cook, Lucy B. [1 ,2 ]
Marks, Sasha [2 ]
Bataillard, Edward [2 ]
Crossette-Thambiah, Christina [2 ]
Sivasubramaniam, Gayathiri [3 ]
Apperley, Jane [1 ,2 ]
Milojkovic, Dragana [1 ,2 ]
机构：
[1] Imperial Coll London, Ctr Haematol, Dept Immunol & Inflammat, London, England
[2] Imperial Coll Healthcare NHS Trust, Dept Haematol, Hammersmith Hosp, London, England
[3] Imperial Coll Healthcare NHS Trust, Dept Resp Med, Hammersmith Hosp, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 190卷 / 04期
关键词：
transplant; infection; COVID-19; immunosupression;
D O I：
10.1111/bjh.16979
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E198 / E200
页数：3
相关论文
共 50 条
  • [21] Tocilizumab for Severe and Critical COVID-19 Pneumonia in Queens, NYC
    Salama, Carlos
    Kaplan-Lewis, Emma
    Durrance, Richard
    Wong, Linda
    Arumugam, Vasanthi
    Fabbri, Marilyn
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2021, 29 (04) : E215 - E220
  • [22] Why tocilizumab could be an effective treatment for severe COVID-19?
    Fu, Binqing
    Xu, Xiaoling
    Wei, Haiming
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [23] Factors related to asymptomatic or severe COVID-19 infection
    Perez-Campos Mayoral, Eduardo
    Teresa Hernandez-Huerta, Maria
    Perez-Campos Mayoral, Laura
    Alberto Matias-Cervantes, Carlos
    Mayoral-Andrade, Gabriel
    Laguna Barrios, Luis Angel
    Perez-Campos, Eduardo
    MEDICAL HYPOTHESES, 2020, 144
  • [24] Severe arterial thrombosis associated with Covid-19 infection
    Kashi, Mahine
    Jacquin, Aurelien
    Dakhil, Bassel
    Zaimi, Rym
    Mahe, Emmanuel
    Tella, Emilie
    Bagan, Patrick
    THROMBOSIS RESEARCH, 2020, 192 : 75 - 77
  • [25] Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state
    McCarthy, Cormac
    Savinelli, Stefano
    Feeney, Eoin R.
    Butler, Marcus W.
    O'Broin, Cathal
    Ryan, Silke
    O'Neill, Lorraine
    Murphy, David J.
    Gallagher, Charles G.
    McKone, Edward F.
    Waqas, Sarmad
    Cotter, Aoife
    Doran, Peter
    Keane, Michael P.
    Mallon, Patrick W.
    RESPIROLOGY, 2020, 25 (10) : 1090 - 1094
  • [26] Tocilizumab for the treatment of COVID-19
    Fernandez-Ruiz, Mario
    Lopez-Medrano, Francisco
    Aguado, Jose Maria
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 431 - 434
  • [27] Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial
    Jelodar, Mohsen Gholinataj
    Rafieian, Shahab
    Saghafi, Fatemeh
    Zedegan, Navid Hadad
    Birjandi, Behnaz
    Rafieian, Shiva
    Dini, Azadeh Allah
    Dehghanpour, Hanieh
    Khalaj, Fatemeh
    Zare, Samira
    Chenari, Hanieh Dehghan
    Hajimaghsoudi, Majid
    Sohrevardi, Seyed Mojtaba
    Mirzaei, Samaneh
    Jamialahmadi, Tannaz
    Atkin, Stephen L.
    Sahebkar, Amirhossein
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115
  • [28] Tocilizumab for the treatment of COVID-19
    Flisiak, Robert
    Flisiak-Jackiewicz, Marta
    Rzymski, Piotr
    Zarebska-Michaluk, Dorota
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (08) : 791 - 797
  • [29] Tocilizumab and COVID-19: Timing of Administration and Efficacy
    Abidi, Emna
    El Nekidy, Wasim S.
    Alefishat, Eman
    Rahman, Nadeem
    Petroianu, Georg A.
    El-Lababidi, Rania
    Mallat, Jihad
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Secondary Infection and Co-infection in COVID-19 Patients Receiving Tocilizumab
    Erdogan, Cagla
    Kilinc, Metin
    Sahin, Beyza
    Sungurtekin, Huelya
    TURKISH JOURNAL OF INTENSIVE CARE-TURK YOGUN BAKIM DERGISI, 2024, 22 (02): : 110 - 115
12345